Related Experiment Videos
Comparative genomic hybridization of low-grade central osteosarcoma
M Tarkkanen1, T Böhling, G Gamberi
1Department of Medical Genetics, Haartman Institute, University of Helsinki, Finland. maija.tarkkanen@helsinki.fi
Summary
Low-grade central osteosarcoma exhibits fewer genetic alterations than high-grade types, indicating lower malignancy. Key changes involve chromosome 12 and 6, with specific gene amplifications observed.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Low-grade central osteosarcoma is a rare bone cancer with poorly understood genetic underpinnings.
- Understanding its cytogenetic and molecular genetic changes is crucial for diagnosis and treatment.
Purpose of the Study:
- To investigate DNA sequence copy number aberrations in low-grade central osteosarcoma.
- To correlate genetic changes with specific gene expression (CDK4, MDM2) and amplification (SAS).
Main Methods:
- Comparative genomic hybridization (CGH) was used to analyze 10 tumor samples.
- Analysis included 7 typical low-grade, 1 low-grade (Grade II), and 2 high-grade recurrences.
- CDK4, MDM2 expression, and SAS amplification were assessed.
Main Results:
- Typical low-grade osteosarcomas showed a single DNA copy number change.
- Advanced tumors (Grade II, recurrences) had a mean of five changes.
- Recurrent aberrations included gains in 12q13-q14, 12p, and 6p21.1-p21.3.
- One tumor with chromosome 12 gain showed MDM2, CDK4 expression, and SAS amplification.
Conclusions:
- The limited number of genetic alterations in low-grade central osteosarcoma reflects its lower malignant potential.
- This contrasts with the complex genomic instability observed in conventional high-grade osteosarcomas.
- Specific chromosomal regions and gene amplifications may play a role in its pathogenesis.